scBench-Long: Verifiable Benchmarking of Long-Horizon Single-Cell Biology

Single-cell studies require analysts to convert raw measurements into specific biological claims through multi-step workflows and integration of metadata, assay context, and auxiliary evidence. Existing AI-biology benchmarks largely measure broad knowledge, executable workflows, or local analysis steps. We introduce scBench-Long, a benchmark for long-horizon single-cell biology in which agents must recover scientific conclusions from raw or near-raw data without prescribed methods. The benchmark contains 21 evaluations spanning melanoma CD8 T-cell reactivity, CD8 RNA+ATAC regulatory inference, human--monkey chimera development, KRAS-driven lung tumor aging, and lethal COVID-19 lung pathology. Tasks cover paired scRNA/TCR sequencing, RNA and chromatin profiling, cross-species transcriptomics, combinatorial scRNA-seq, single-nucleus RNA-seq, immune repertoires, ortholog maps, ligand--receptor resources, and validation evidence. Candidate claims are reproduced, reviewed, and converted into controlled answer vocabularies with deterministic grading and trajectory rubrics. Across 1,068 completed trajectories, the strongest model--harness pair passes 16/63 runs (25.4\%). scBench-Long evaluates whether agents can move beyond local analysis steps and make complex scientific claims that are supported by single-cell data.

TxBench-PP: Analyzing AI Agent Performance on Small-Molecule Preclinical Pharmacology

Artificial intelligence (AI) agents promise to accelerate drug discovery by compressing interpretation and decision-making loops, but practical deployment requires trusted evaluation on realistic program decisions. We introduce TherapeuticsBench Preclinical Pharmacology (TxBench-PP), a verifiable benchmark for small-molecule preclinical pharmacology and the first focused slice of a broader TherapeuticsBench effort across drug-discovery stages and therapeutic modalities. TxBench-PP tests whether agents can recover accurate conclusions from real-world assay data rather than memorized facts from literature. The benchmark contains 100 evaluations indexed by program stage, assay type, and task structure, spanning mechanism-of-action (MoA) and pharmacodynamic (PD) reasoning, compound-target engagement, causal target validation, developability and safety, and translational efficacy. Agents receive realistic workflow snapshots, inspect files in a coding environment, and return structured answers graded deterministically. Across 16 model-harness configurations, comprising 11 models and 4,800 trajectories, no system reliably recovered preclinical pharmacology decisions. The strongest configuration, Claude Opus 4.8 / Pi, passed 59.3\% of endpoint attempts (178/300; 95\% CI, 51.1-67.6), followed by GPT-5.5 / Pi at 55.3\% (166/300; 47.0-63.6).

EpiBench: Verifiable Evaluation of AI Agents on Epigenomics Analysis

We introduce EpiBench, a verifiable benchmark for short-horizon epigenomics analysis. EpiBench evaluates whether agents can make well-defined analysis decisions from realistic workflow states and return deterministically gradable answers. The benchmark includes 106 evaluations across CUT\&Tag/CUT\&RUN, ATAC-seq, ChIP-seq, and DNA methylation workflows. Across 5,088 valid trajectories from 16 model-harness pairs, no system passed a majority of attempts: GPT-5.5 / Pi led at 45.0\% (143/318 attempts; 95\% confidence interval (CI), 36.3--53.7), followed by GPT-5.5 / OpenAI Codex at 39.9\% (127/318 attempts; 95\% CI, 31.6--48.3). Claude Opus 4.8 Max / Pi and GPT-5.4 / Pi each passed 39.0\% (124/318 attempts; 95\% CI, 30.2--47.8 and 31.0--47.0, respectively). Performance varies across assay types, and many failed runs still contain parts of the correct answer. Agents often found the right files and computed useful intermediate results, but failed when the task required deeper, assay-specific scientific judgment.

Verifiable Benchmarking of Long-Horizon Spatial Biology

AI agents are increasingly useful for biological data analysis, but existing benchmarks mostly test broad biological knowledge, executable workflows, or localized analysis steps rather than end-to-end scientific reasoning over spatial measurements. We introduce SpatialBench-Long, a benchmark for long-horizon spatial biology in which agents must recover biological claims from raw or near-raw data and calibrated experimental context without prescribed methods. SpatialBench-Long contains 24 evaluations across primary pancreatic ductal adenocarcinoma (PDAC), engineered glioblastoma organoids and in vivo tumors, Cas9 lineage-traced lung adenocarcinoma, and mouse optic nerve aging/intervention systems, spanning CosMx, Visium, Xenium, multiplexed error-robust fluorescence in situ hybridization (MERFISH), single-cell RNA sequencing (scRNA-seq), Slide-seq, Slide-tags, histology, and lineage-recording data. Candidate claims are hardened through reproduction, independent scientist review, and trajectory inspection. Final answers are graded deterministically over controlled vocabularies and symbols with companion rubrics capturing progress through key analysis chokepoints. Across the SpatialBench-Long benchmark, three model-harness pairs tie at 8/72 runs (11.1\%): Gemini 3.5 Flash / Pi terminal coding harness, GPT-5.5 / Pi, and GPT-5.5 / OpenAI Codex. SpatialBench-Long tests whether agents can move beyond executing procedural analysis to deriving accurate scientific conclusions from complex spatial measurements.